Barclays Upgrades Clariant as Dutch Court Ruling Eases Litigation Overhang

Barclays has upgraded Clariant to "Overweight" from "Equal Weight," citing a favorable court ruling that significantly reduces the legal and financial risks associated with a multi-billion-franc litigation overhang. The bank also raised its price target on the Swiss specialty chemicals company by 44% to 11.50 Swiss francs.

Court Ruling De-risks Billions in Claims

The upgrade follows a July 29 decision by the Amsterdam District Court to dismiss a €1 billion ethylene cartel damages claim brought by Shell. According to Barclays, the court rejected Shell's damage calculation model and concluded the energy giant failed to prove the alleged cartel caused it financial loss.

This ruling is significant as it materially de-risks Clariant's wider portfolio of outstanding claims, which totals over 9 billion Swiss francs. Barclays noted that nearly half of the remaining claims are slated to be heard in Dutch courts using similar methodologies, potentially setting a precedent.

Analyst Price Target and Valuation

Reflecting the reduced legal liability, Barclays lifted its price target for Clariant to 11.50 Swiss francs from a previous 8 francs. The bank has lowered its assumed litigation liability for the company to 0.8 billion francs from a prior market-implied estimate of 2 billion francs.

Ad

Barclays also highlighted a valuation gap as a key factor in the upgrade, pointing out that Clariant trades at a discount to its peers.

• Clariant's forward EV/EBITDA multiple is approximately 7.8x.
• This compares to competitors AkzoNobel at 9.2x, Elementis at 9x, and Croda at 11x.

Market Reaction and Outlook

Clariant shares rallied 16% following the court's decision. However, Barclays believes this move only priced in the removal of about 0.4 billion francs of expected liability, suggesting further potential upside.

While Shell has until October 29 to appeal the ruling—an action Barclays considers "more likely than not"—the bank assesses the risk to Clariant from a potential appeal as low. Barclays also projects Clariant's full-year 2026 adjusted EBITDA at 681 million francs, about 3% above the market consensus.